ADHD Linked to Significantly Higher Early Death Rate, Medication May Offer Protection

Individuals diagnosed with attention-deficit/hyperactivity disorder (ADHD) experience a 71% higher overall risk of early death compared to those without the condition, according to a recent review published in JAMA Network Open. However, the study also suggests that taking prescribed ADHD medication may provide a protective effect, potentially lowering this elevated risk.

The research synthesized data from 19 observational studies that included nearly 16 million participants across three continents, aiming to assess the long-term mortality associated with ADHD. The analysis considered both unnatural causes of death, such as suicide and injuries, and natural causes, including cardiovascular disease and diabetes.

Across all examined categories, people with ADHD exhibited higher mortality rates than their counterparts without the diagnosis. Senior author Joshua Stott, a professor at University College London, stated that the review found an increased risk of death not only from suicide and injury but also from natural causes, highlighting the wide-ranging health inequalities faced by individuals with ADHD.

The risk of death from suicide was nearly doubled, showing an 89% increase, while the risk of dying from intentional or unintentional injuries, like motor vehicle accidents, was 55% higher. The study also noted a 27% higher risk of death from natural causes among those with ADHD.

This increased risk from natural causes was often linked to factors such as smoking and substance use, as well as executive function challenges. These challenges can make it more difficult for individuals to manage chronic health conditions, attend medical appointments, and adhere to treatment plans.

In a subset of the analysis, researchers investigated the impact of medical treatment on mortality rates. Among individuals with ADHD, those taking prescribed medication demonstrated a 25% lower risk of death from any cause compared to those not on medication. This suggests that effective treatment could mitigate some of the behavioral effects and associated health risks of the condition.

"ADHD is not by definition a life-limiting condition, as the right support and treatment can help people live long and healthy lives," Stott said. "Our findings underscore the importance of ensuring that everyone who may have ADHD has access to accurate diagnosis and treatment."

Despite the findings, the researchers acknowledged several limitations. All studies included were observational, meaning they identify associations rather than establish direct cause-and-effect relationships. The findings regarding ADHD medication were based on a smaller group of people from only three of the 19 studies, indicating preliminary results that require further investigation.

Variations across studies, stemming from differences in diagnostic criteria, healthcare access, and tracking methods, also contributed to the wide range of results. Underlying factors like socioeconomic status and other mental health conditions were not consistently controlled for across the datasets.

"Our findings provide early evidence to suggest that medication may play an important role in supporting the health of people with ADHD, but this is based on a small number of studies and further research is needed to clarify this link," said first author Lucy Corrigan, a research assistant at the University of Liverpool. "Medication is just part of the story; many people with ADHD benefit from comprehensive, long-term treatment and support."